A new live bacterial therapy for Crohn’s disease
Official title: A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease
Funded at Rise Therapeutics, LLC · NIH-11308837 · Data updated 2026-11-12
A novel live biotherapeutic product called R-3750 is being studied to help people with Crohn’s disease by safely modulating gut immunity and restoring gut balance.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rise Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Rockville, UNITED STATES) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,042,478 |
| NIH project number | 1R44DK146369-01 |
| Project ID | NIH-11308837 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Crohn’s disease who meet the study’s specific inclusion criteria.
✕Less likely to help
Patients who do not meet eligibility or do not respond to this kind of therapy may not benefit.
What this research studies
This project tests an engineered live bacterium, given as an oral treatment, to calm inflammation in the gut of adults with Crohn’s disease. It builds on safety and signals seen in a Phase 1 trial for ulcerative colitis and aims to translate that approach to Crohn’s disease. Researchers will monitor safety, clinical outcomes, and immune and microbiome changes to see if R-3750 can improve gut integrity and symptoms. If successful, this work could lead to a new targeted therapy that works with the body’s own gut ecosystem.
Why it matters
Potential benefit: If successful, patients could experience reduced inflammation and symptom relief with a novel oral therapy.
How similar studies have gone: Previous work in similar live biotherapeutics has shown safety signals and potential clinical activity in inflammatory bowel diseases, but Crohn’s-specific results are still emerging.
Where this research is happening
-
Rise Therapeutics, LLC
Rockville, United States Active
Researchers
- Principal investigator: Furlan Freguia, Christian — Rise Therapeutics, LLC
- Study coordinator: Furlan Freguia, Christian
Related research
Other NIH-funded projects on the same topics.
-
Site-specific gene-microbial interactions in children with Crohn’s disease
A child-focused study explores how genes and gut microbes interact in very young children with Crohn’s disease to understand why the disease starts and how it might be treated.
-
Ultrasound markers to measure Crohn’s disease activity
A Mayo Clinic team is testing new 3D ultrasound methods to reliably track inflammation and scarring in Crohn’s disease using safe, affordable imaging that could replace more costly scans.
-
Understanding abnormal sugar building blocks in Crohn’s disease to guide smarter therapies
This project looks at how a specific genetic variation affects how Crohn’s disease works and whether targeting that pathway could lead to new treatments.
-
AI and single-cell tests to predict Crohn's disease course in children
This project uses artificial intelligence plus single-cell and other molecular data to predict which children and teens with Crohn's disease will have mild versus severe or treatment‑resistant disease.
-
How IL-23 Blockade in Crohn's Disease Changes Immune Cells
This study looks at how the IL-23 blocking therapy risankizumab affects immune cells in people with Crohn’s disease.
-
Metabolic signatures that predict outcomes in children with Crohn's
This project looks at metabolism patterns in children with Crohn's disease to help predict how their condition will progress and respond to treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.